Study: CBD-Rich Cannabis Extracts Present “a Better Therapeutic Profile” Than Pure CBD

CBD-rich extracts which contain at least a small amounts of other cannabinoids “present a better therapeutic profile” than CBD alone, according to a new study published by the journal Frontiers in Neurology.

Cannabis oil (photo: David Downs).

The study, titled Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy, states that the improved benefits of high-CBD cannabis extracts over pure CBD “is likely due to synergistic effects of CBD with other phytocompounds (aka Entourage effect)”.

According to the study’s abstract. “This meta-analysis paper describes the analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Beyond attempting to establish the safety and efficacy of such products, we also investigated if there is enough evidence to assume any difference in efficacy between CBD-rich extracts compared to purified CBD products.”

Read moreStudy: CBD-Rich Cannabis Extracts Present “a Better Therapeutic Profile” Than Pure CBD

Study: CBD Reduces Salience and Pleasantness of Cigarettes

According to a new study published by the journal Addiction, a single dose of cannabidiol (CBD) reduces the salience and pleasantness of cigarette cues, compared with a placebo.

“Cannabidiol (CBD), a non-intoxicating cannabinoid, may be a promising novel smoking cessation treatment due to its anxiolytic properties, minimal side-effects and research showing it may modify drug cue salience”, begins the abstract of this “Randomized, double-blind crossover study with a fixed satiated session followed by two overnight abstinent sessions.”

For the study, researchers “used an experimental medicine approach with dependent cigarette smokers to investigate if (1) overnight nicotine abstinence, compared with satiety, will produce greater attentional bias (AB), higher pleasantness ratings of cigarette-related stimuli and increased craving and withdrawal; (2) CBD in comparison to placebo, would attenuate AB, pleasantness of cigarette-related stimuli, craving and withdrawal and not produce any side-effects.”

Read moreStudy: CBD Reduces Salience and Pleasantness of Cigarettes

Study: Cannabidiol May Help Prevent Relapses in Those Addicted to Alcohol and Drugs

The findings of a study published last week by the journal Neuropsychopharmacology “provide proof of principle supporting potential of CBD [cannabidiol] in relapse prevention”.

“Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders”, states the study’s abstract. “Recently, CBD has also been explored for potential in treating drug addiction.” The study notes that substance use disorders “are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to stress, elevated anxiety, and impaired impulse control.” Here, researchers “evaluated the “anti-relapse” potential of a transdermal CBD preparation in animal models of drug seeking, anxiety and impulsivity.”

For the study, rats with alcohol or cocaine self-administration histories “received transdermal CBD at 24 h intervals for 7 days and were tested for context and stress-induced reinstatement, as well as experimental anxiety on the elevated plus maze.” Effects on impulsive behavior were established using “a delay-discounting task following recovery from a 7-day dependence-inducing alcohol intoxication regimen.”

Read moreStudy: Cannabidiol May Help Prevent Relapses in Those Addicted to Alcohol and Drugs

UK: CBD Use Doubles in One Year

According to a new report the number of people in the United Kingdom who use cannabidiol (CBD) oil has doubled since last year.

According to the report from the Cannabis Trades Association U.K. (CTAUK), 250,000 people currently use CBD oil to help treat a variety of medical conditions. These numbers are up from 125,000 last year, an 100% increase. According to CTAUK, there are approximately 1,000 new people each month who use CBD oil.

The increase comes after the U.K. government officially recognized CBD as medicine, stating that it has “restoring, correcting, or modifying” properties. The statement opened the door for companies to obtain licenses to distribute CBD oil.

Read moreUK: CBD Use Doubles in One Year

Study: CBD a “Therapeutic Candidate for Stroke Prevention”

Cannabidiol (CBD) may help to prevent strokes, according to a new study published by the U.S. National Institute of Health.

“The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states”, begins the study’s abstract, which was published in-print by the journal Cannabis and Cannabinoid Research. “The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling.”

Cannabidiol (CBD), a nonpsychoactive constituent of Cannabis, “is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets.” According to reseachers, this “speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.”

Read moreStudy: CBD a “Therapeutic Candidate for Stroke Prevention”

Single Dose of CBD Reduces Blood Pressure, Finds Randomized, Placebo-Controlled, Double-Blind, Crossover Study

Just a single dose of cannabidiol (CBD) reduces blood pressure, indicating it may play a role in the treatment of cardiovascular disorders, according to a new study published by the journal JCI Insight.

According to researchers, the aim of this study “was to investigate if CBD reduces BP [blood pressure] in humans.” To determine this, “Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using a finometer and laser Doppler.”

CBD “reduced resting systolic BP (–6 mmHg; P < 0.05) and stroke volume (–8 ml; P < 0.05), with increased heart rate (HR) and maintained cardiac output. Subjects who had taken CBD had lower BP (–5 mmHg; P < 0.05, especially before and after stress), increased HR (+10 bpm; P < 0.01), decreased stroke volume (–13 ml; P < 0.01), and a blunted forearm skin blood flow response to isometric exercise.’ In response to cold stress, “subjects who had taken CBD had blunted BP (–6 mmHg; P < 0.01) and increased HR (+7 bpm; P < 0.05), with lower total peripheral resistance.”

Read moreSingle Dose of CBD Reduces Blood Pressure, Finds Randomized, Placebo-Controlled, Double-Blind, Crossover Study

Government Seeking Public Comments on Cannabidiol (CBD)

The government is seeking public comments on a variety of substances, including the cannabis-derived compound cannabidiol, commonly referred to as CBD.

Specifically, the Food and Drug Administration (FDA) is “requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances”, including CBD. According to t he FDA, these comments “will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs.” WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs. The notice requesting comments is required by the Controlled Substances Act (the CSA).

Currently CBD is defined as a schedule I controlled substance, putting it on equal footing as hard drugs like heroin. This is despite numerous states allowing CBD for medical use, and despite a plethora of research showing its medical efficacy.

Read moreGovernment Seeking Public Comments on Cannabidiol (CBD)

Study: CBD Blocks Opioid Reward, May Help Treat Addiction

According to a new study published in the journal Planta Medica, cannabidiol blocks the reward of opioids and as such may be useful in treating those addicted to them.

This study, conducted by researchers at the University of Mississippi and Oxford, “sought to determine whether the cannabis constituent cannabidiol attenuates the development of morphine reward in the conditioned place preference paradigm.” Separate groups of mice “received either saline or morphine in combination with one of four doses of cannabidiol using three sets of drug/no-drug conditioning trials.”

After drug-place conditioning, “morphine mice displayed robust place preference that was attenuated by 10 mg/kg cannabidiol.” Further, “when administered alone, this dose of cannabidiol was void of rewarding and aversive properties.”

Read moreStudy: CBD Blocks Opioid Reward, May Help Treat Addiction

Study: CBD May Treat Psychiatric/Cognitive Symptoms Associated with Neurodegeneration

Cannabidiol (CBD) may be beneficial in the treatment of psychiatric/cognitive symptoms associated with neurodegeneration, according to a new study.

The study, published by the journal Frontiers in Pharmacology, was also published online by the U.S. National Institute of Health.

“Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression”, begins the study’s abstract. “The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes.”

Read moreStudy: CBD May Treat Psychiatric/Cognitive Symptoms Associated with Neurodegeneration

New Study: Cannabidiol (CBD) Exhibits Strong Anti-Seizure Properties

A new study published by the journal Neurochemical Research, and published online by the U.S. National Institute of Health, has confirmed past research that shows cannabidiol to be an anti-seizure agent.

For the study; “The National Institute of Neurological Disorders and Stroke (NINDS) funded Epilepsy Therapy Screening Program (ETSP) investigated CBD in a battery of seizure models using a refocused screening protocol aimed at identifying pharmacotherapies to address the unmet need in pharmacoresistant epilepsy”.

Applying this new screening workflow, CBD was investigated in multiple mouse and rat models of acute seizures. Following intraperitoneal (i.p.) pretreatment, “CBD produced dose-dependent protection in the acute seizure models.” In chronic models, “CBD produced dose-dependent protection in the corneal kindled mouse”.

Read moreNew Study: Cannabidiol (CBD) Exhibits Strong Anti-Seizure Properties